


## Medicines & Healthcare products Regulatory Agency

## Visual risk communication diagram to be used by a healthcare professional when counselling on the risks

This information does not replace the overall discussion on risks and benefits which would lead to an informed prescribing decision.



This visual risk diagram should be viewed with the understanding that there are limitations to the data including:

- the study did not include a group of patients who were not taking either valproate or lamotrigine or levetiracetam and so the background risk in an untreated population of patients with these conditions is not known.
- it was not possible to look at the severity or the type of neurodevelopmental disorders between groups.
- a comparison was only made between fathers taking valproate and lamotrigine or levetiracetam and so findings cannot be drawn on the potential risk in comparison to other anti-seizure medications.
- the study only looked at patients who were on one medicine (valproate and lamotrigine or levetiracetam).